• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CMRX

    Chimerix Inc.

    Subscribe to $CMRX
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: chimerix.com

    Peers

    $DCPH

    Recent Analyst Ratings for Chimerix Inc.

    DatePrice TargetRatingAnalyst
    5/23/2023$7.00Outperform
    Robert W. Baird
    9/7/2022$7.00Overweight
    CapitalOne
    12/22/2021$21.00 → $24.00Buy
    HC Wainwright & Co.
    11/22/2021$19.00 → $21.00Buy
    HC Wainwright & Co.
    See more ratings

    Chimerix Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Vakiener Victoria

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:17:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Sherman Michael A. returned $3,620,138 worth of shares to the company (423,408 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:16:42 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO and CCO Riga Thomas J returned $520,079 worth of shares to the company (60,828 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:15:59 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Multani Pratik S

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:15:11 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Middleton Fred A returned $30,912,328 worth of shares to the company (3,615,477 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:14:24 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Meyer Robert J. returned $300,532 worth of shares to the company (35,150 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:13:33 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Melemed Allen S. returned $1,486,435 worth of shares to the company (173,852 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:12:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Laspaluto Michelle returned $1,552,176 worth of shares to the company (181,541 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:11:49 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kozin Marc D

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:11:08 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP OF FINANCE AND ACCOUNTING Jakeman David returned $1,335,587 worth of shares to the company (156,209 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:10:22 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Middleton Fred A bought $16,522 worth of shares (17,295 units at $0.96) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      11/20/23 3:28:44 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,489 worth of shares (2,705 units at $0.92) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      11/13/23 4:39:41 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $19,636 worth of shares (20,000 units at $0.98) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      9/26/23 3:58:48 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

      New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

      3/21/25 6:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, wi

      3/7/25 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

      -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") and Chimerix (NASDAQ:CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both compani

      3/5/25 7:00:00 AM ET
      $CMRX
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 270,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four yea

      2/18/25 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

      Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma PDUFA Target Action Date of August 18, 2025 No Advisory Committee Meeting Currently Planned to Discuss Application DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The application has been granted Priority Review

      2/18/25 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

      DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET. An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a b

      1/29/25 4:15:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four ye

      1/24/25 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Speak Today at The White House Cancer Moonshot Forum

      DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced today that Dr. Joshua E. Allen, Chief Scientific Officer at Chimerix, will speak at the Biden Cancer Moonshot Mission Report 2024 – And Beyond. Dr. Allen's remarks will cover the program's impact on advancing therapies for brain and rare pediatric cancers, including H3 K27M-mutant diffuse glioma. "The Biden Cancer Moonshot has significantly improved the approach to cancer diagnosis and treatment with, among other achievements, programs to improve health eq

      1/13/25 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

      DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today confirms that the Company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the United States. "This NDA submission marks a pivotal moment for Chimerix in our mission to bring this potentially life-altering drug to patients diagnosed with recurrent H3 K27M-mutant diffuse glioma," said Mike Andriole, Ch

      12/30/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

      Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recu

      12/9/24 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. Financials

    Live finance-specific insights

    See more
    • Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

      New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

      3/21/25 6:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

      Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recu

      12/9/24 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

      – Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2024 and provided an operational update. "We have sustaine

      11/7/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

      DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time and refer to conference ID 6580777. A live audio webcast of the call will also be availab

      11/1/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update

           – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2024 and provided an operational

      8/13/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024

      DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on

      8/6/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

      – Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients

      5/1/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

      DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220. A live audio webcast of the call will also be available on

      4/24/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

      – ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update. "Following strong clinical development in 2

      2/29/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

      – Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update. "The third quarter was marked by strong progress across our first-

      11/2/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Chimerix with a new price target

      Robert W. Baird initiated coverage of Chimerix with a rating of Outperform and set a new price target of $7.00

      5/23/23 7:29:20 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Chimerix with a new price target

      CapitalOne initiated coverage of Chimerix with a rating of Overweight and set a new price target of $7.00

      9/7/22 8:57:44 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

      HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $24.00 from $21.00 previously

      12/22/21 6:12:39 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

      HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $21.00 from $19.00 previously

      11/22/21 11:55:24 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

      HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $19.00 from $18.00 previously

      6/7/21 6:11:27 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

      HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $18.00 from $16.00 previously

      5/6/21 12:47:23 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Chimerix with a new price target

      Maxim Group initiated coverage of Chimerix with a rating of Buy and set a new price target of $20.00

      4/29/21 8:01:28 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen resumed coverage on Chimerix with a new price target

      Cowen resumed coverage of Chimerix with a rating of Outperform and set a new price target of $18.00 from $10.00 previously

      4/23/21 6:56:10 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Chimerix with a new price target

      Wedbush initiated coverage of Chimerix with a rating of Outperform and set a new price target of $14.00

      3/31/21 7:58:47 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Chimerix with a new price target

      Jefferies initiated coverage of Chimerix with a rating of Buy and set a new price target of $21.00

      3/31/21 7:57:53 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Chimerix Inc.

      15-12G - CHIMERIX INC (0001117480) (Filer)

      5/1/25 8:51:45 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Chimerix Inc.

      EFFECT - CHIMERIX INC (0001117480) (Filer)

      4/23/25 12:15:12 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:54:30 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:52:18 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:50:44 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:49:07 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:47:32 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:46:06 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:44:25 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:43:18 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/14/24 5:01:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/12/24 6:06:37 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chimerix Inc.

      SC 13G - CHIMERIX INC (0001117480) (Subject)

      9/29/23 4:54:06 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chimerix Inc.

      SC 13G - CHIMERIX INC (0001117480) (Subject)

      5/2/23 5:07:24 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/14/23 4:11:38 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/13/23 4:05:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/13/23 10:47:56 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Chimerix Inc.

      SC 13D - CHIMERIX INC (0001117480) (Subject)

      11/10/22 3:05:23 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chimerix Inc.

      SC 13G - CHIMERIX INC (0001117480) (Subject)

      7/5/22 1:39:44 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chimerix Inc.

      SC 13G - CHIMERIX INC (0001117480) (Subject)

      5/2/22 5:15:02 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Chimerix Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Chimerix Appoints Marc D. Kozin to Board of Directors

      DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

      3/21/24 7:00:00 AM ET
      $CMRX
      $UFPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Chimerix Appoints Lisa Decker to Board of Directors

      DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. "We are delighted to welcome Lisa to the Chimerix Board of Directors. She brings a wealth of scientific expertise, oncology drug development and business development experience that will be important assets to

      12/29/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

      DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. "We are excited to welcome Tom to the Chimerix team as his leadership and extensive market knowledge will be a great asset as we advance ONC201 toward commercialization," said Mike Andriole, Chief Executive Officer of Chimerix. "Tom's in-depth oncology experience in commercial launch readiness, brand marketing, market access, and reimbursement will accelerate our readiness efforts

      11/16/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs

      DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today appointed Christopher L. Jordan as Vice President, Regulatory Affairs. "We are pleased to announce the addition of Christopher Jordan to our leadership team as VP of Regulatory Affairs. Christopher brings over 30 years of pharmaceutical experience across various stages of product development. Some on our management team have had the pleasure of working with Christopher several years ago at Endocyte and Novartis where he recently led the regulatory strategy and

      8/8/22 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Appoints Vicki Vakiener to Board of Directors

      DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Vicki Vakiener to its Board of Directors, effective immediately. Ms. Vakiener currently serves as Chief Commercial Officer of Epizyme Inc. "We are thrilled to welcome Vicki to our Board of Directors. She brings a tremendous amount of oncology commercial leadership experience to our Board as we advance our late stage programs," said Mike Sherman, President and Chief Executive Officer of Chimerix. "The diversity of Vicki's capabilities across every aspect of t

      4/26/21 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care